Acinetobacter pneumonia: Improving outcomes with early identification and appropriate therapy

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


In an era of increasing antimicrobial resistance, Acinetobacter distinguishes itself as one of the most resistant Gram-negative bacteria responsible for significant morbidity and mortality. New solutions are needed to combat the detrimental effects of increasing rates of antimicrobial resistance. Using empiric broad-spectrum antibiotics in patients deemed at risk for infections caused by multidrug-resistant pathogens may protect against attributable mortality, but this temporary solution furthers the risk of antimicrobial resistance. In this article we will review relevant strategies to aid with early identification and appropriate treatment of Acinetobacter pneumonia while preserving antibiotic susceptibility.

Original languageEnglish
Pages (from-to)1455-1462
Number of pages8
JournalClinical Infectious Diseases
Issue number9
StatePublished - Oct 15 2018


  • Acinetobacter
  • antimicrobial resistance
  • early antibiotics
  • rapid diagnostics


Dive into the research topics of 'Acinetobacter pneumonia: Improving outcomes with early identification and appropriate therapy'. Together they form a unique fingerprint.

Cite this